Margetuximab Expanded Access Program

Neoadjuvant Therapy With Herceptin and Taxol for Breast Cancer

NCT00136539 ·Status: COMPLETED ·Phase: PHASE2

A Clinical Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer

NCT07043725 ·Status: RECRUITING ·Phase: PHASE3

Efficacy of TQB2102 Versus TCbHP in Neoadjuvant Therapy for HER2-positive Early Breast Cancer.

NCT07136974 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2

Testing Radiation and HER2-targeted Therapy Versus HER2-targeted Therapy Alone for Low-risk HER2-positive Breast Cancer

NCT05705401 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

Study of ACTR T Cell Product in Combination With Trastuzumab in Subjects With HER2-Positive Advanced Solid Tumor Cancers

NCT03680560 ·Status: TERMINATED ·Phase: PHASE1

Hormonal Receptor (HR)-Positive HER2 Negative Breast Cancer Patients Treated With Preoperative ELacestrant and PULSAR Radiotherapy

NCT07005882 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2

HER2(Human Epidermal Growth Factor Receptor 2) -Positive Metastatic Breast Cancer in Russia

NCT05905939 ·Status: COMPLETED

Chemotherapy-free Trastuzumab and Pertuzumab in HER2-positive Breast Cancer: FDG-PET Response-adapted Strategy.

NCT03161353 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

Clinical Trial of Atezolizumab With Paclitaxel, Trastuzumab, and Pertuzumab in Patients With Metastatic HER-2 Positive Breast Cancer

NCT03125928 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

Adopting the MRD Strategy to Optimize Post-operation Adjuvant Therapies for Early Stage Breast Cancer

NCT05345860 ·Status: RECRUITING ·Phase: NA

Testing Whether Treating Breast Cancer Metastases With Surgery or High-Dose Radiation Improves Survival

NCT02364557 ·Status: COMPLETED ·Phase: PHASE2/PHASE3

Higher Per Daily Treatment-Dose Radiation Therapy or Standard Per Daily Treatment Radiation Therapy in Treating Patients With Early-Stage Breast Cancer That Was Removed by Surgery

NCT01349322 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

Real-World Treatment Patterns and Outcomes in HER2-Altered Metastatic Breast Cancer Patients in the United States

NCT07342309 ·Status: ACTIVE_NOT_RECRUITING

Association Between HER2 Status and pCR Rate in ER-positive Breast Cancer Receiving Neoadjuvant Endocrine or Chemotherapy

NCT05673850 ·Status: COMPLETED

Efficacy and Safety Study of EG1206A (EirGenix' Pertuzumab) Compared With EU-sourced Perjeta® (Pertuzumab) in Patients With HER2-positive Hormone Receptor Negative Early Breast Cancer.

NCT06884254 ·Status: WITHDRAWN ·Phase: PHASE3

A Study of Herceptin (Trastuzumab) in Women With Human Epidermal Growth Factor Receptor (HER) 2-Positive Advanced and/or Metastatic Breast Cancer

NCT02748213 ·Status: COMPLETED ·Phase: PHASE2

A Study Evaluating Pertuzumab (Perjeta) Combined With Trastuzumab (Herceptin) and Standard Anthracycline-based Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced, Inflammatory, or Early-stage Breast Cancer

NCT02132949 ·Status: COMPLETED ·Phase: PHASE2

TCb vs EC-T in High Risk ER+/HER2- Breast Cancer

NCT05901428 ·Status: RECRUITING ·Phase: PHASE3

PersonaLized neoAdjuvant Strategy ER Positive and HER2 Negative Breast Cancer TO Increase BCS Rate

NCT03900637 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

Cardiac Safety Study in Patients With HER2 + Breast Cancer

NCT01904903 ·Status: COMPLETED ·Phase: PHASE2

AZD2014 and Fulvestrant in Patients With ER+ Advanced Metastatic Breast Cancer

NCT01597388 ·Status: COMPLETED ·Phase: PHASE1

Neoadjuvant Therapy in Clinical Stage I-III HER2-positive Breast Cancer.

NCT02789657 ·Status: COMPLETED ·Phase: PHASE2

Evaluation of HER2DX Assay on Treatment Decisions in Patients With Early Stage HER2+ Breast Cancer: the HER2BREASTDX

NCT06723990 ·Status: RECRUITING

HER2-positive Breast Cancer Project Initiated by Investigators

NCT05346328 ·Status: UNKNOWN ·Phase: PHASE2

A Study to Investigate Efficacy and Safety With Oral AZD9833 Compared With Intramuscular Fulvestrant in Post-menopausal Women at Least 18 Years of Age With Advanced ER-positive HER2 Negative Breast Cancer

NCT04214288 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2